JunShiBio: 2025 revenue growth of 28.23% to 2.498 billion yuan, with commercialized pharmaceutical sales revenue increasing compared to the same period last year

LightningPacketLoss · 2026-03-16T14:03:38+00:00

Junshi Biosciences announced that operating revenue for 2025 reached 2.498 billion yuan, representing a year-over-year growth of 28.23%; net loss attributable to parent company was 875 million yuan, with a narrowed loss margin. The company decided not to proceed with profit distribution or capital reserve conversion to share capital. The growth in operating revenue was primarily driven by increased sales of commercialized products.

LightningPacketLoss

2026-03-16 14:03:38

Abstract generation in progress

Recently, Junshi Biosciences announced that in 2025, the company achieved operating revenue of 2.498 billion yuan, a year-on-year increase of 28.23%. The net profit attributable to the parent company’s owners was a loss of 875 million yuan, compared to a loss of 1.281 billion yuan in the same period last year. The company will not distribute profits or convert capital reserves into share capital for the 2025 fiscal year.

The year-on-year growth in operating revenue is mainly due to increased sales revenue from commercialized drugs compared to the same period last year. The reduction in net loss attributable to shareholders of the listed company compared to the same period last year is primarily due to increased sales revenue from commercialized drugs.

(Junshi Biosciences Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.